Taiwan
· Delayed Price · Currency is TWD Taiyen Biotech Statistics
Total Valuation
Taiyen Biotech has a market cap or net worth of TWD 6.56 billion. The enterprise value is 4.92 billion.
| Market Cap | 6.56B |
| Enterprise Value | 4.92B |
Important Dates
The next estimated earnings date is Friday, August 1, 2025.
| Earnings Date | Aug 1, 2025 |
| Ex-Dividend Date | Aug 20, 2024 |
Share Statistics
Taiyen Biotech has 200.00 million shares outstanding. The number of shares has increased by 0.06% in one year.
| Current Share Class | 200.00M |
| Shares Outstanding | 200.00M |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | -0.55% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 11.84% |
| Float | 108.05M |
Valuation Ratios
The trailing PE ratio is 18.02.
| PE Ratio | 18.02 |
| Forward PE | n/a |
| PS Ratio | 2.02 |
| PB Ratio | 0.97 |
| P/TBV Ratio | 0.97 |
| P/FCF Ratio | 26.85 |
| P/OCF Ratio | 11.75 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.41, with an EV/FCF ratio of 20.15.
| EV / Earnings | 13.51 |
| EV / Sales | 1.52 |
| EV / EBITDA | 8.41 |
| EV / EBIT | 13.74 |
| EV / FCF | 20.15 |
Financial Position
The company has a current ratio of 2.82, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.82 |
| Quick Ratio | 2.25 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.24 |
| Debt / FCF | 0.58 |
| Interest Coverage | 53.16 |
Financial Efficiency
Return on equity (ROE) is 4.78% and return on invested capital (ROIC) is 3.25%.
| Return on Equity (ROE) | 4.78% |
| Return on Assets (ROA) | 2.70% |
| Return on Invested Capital (ROIC) | 3.25% |
| Return on Capital Employed (ROCE) | 4.91% |
| Revenue Per Employee | 7.21M |
| Profits Per Employee | 809,813 |
| Employee Count | 450 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 5.20 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.24% in the last 52 weeks. The beta is 0.18, so Taiyen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -3.24% |
| 50-Day Moving Average | 32.10 |
| 200-Day Moving Average | 32.92 |
| Relative Strength Index (RSI) | 56.00 |
| Average Volume (20 Days) | 73,671 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Taiyen Biotech had revenue of TWD 3.24 billion and earned 364.42 million in profits. Earnings per share was 1.82.
| Revenue | 3.24B |
| Gross Profit | 1.31B |
| Operating Income | 358.27M |
| Pretax Income | 430.10M |
| Net Income | 364.42M |
| EBITDA | 574.51M |
| EBIT | 358.27M |
| Earnings Per Share (EPS) | 1.82 |
Balance Sheet
The company has 1.77 billion in cash and 140.70 million in debt, giving a net cash position of 1.63 billion or 8.16 per share.
| Cash & Cash Equivalents | 1.77B |
| Total Debt | 140.70M |
| Net Cash | 1.63B |
| Net Cash Per Share | 8.16 |
| Equity (Book Value) | 6.76B |
| Book Value Per Share | 33.81 |
| Working Capital | 1.86B |
Cash Flow
In the last 12 months, operating cash flow was 558.35 million and capital expenditures -314.07 million, giving a free cash flow of 244.28 million.
| Operating Cash Flow | 558.35M |
| Capital Expenditures | -314.07M |
| Free Cash Flow | 244.28M |
| FCF Per Share | 1.22 |
Margins
Gross margin is 40.43%, with operating and profit margins of 11.04% and 11.23%.
| Gross Margin | 40.43% |
| Operating Margin | 11.04% |
| Pretax Margin | 13.26% |
| Profit Margin | 11.23% |
| EBITDA Margin | 17.71% |
| EBIT Margin | 11.04% |
| FCF Margin | 7.53% |
Dividends & Yields
This stock pays an annual dividend of 1.30, which amounts to a dividend yield of 3.99%.
| Dividend Per Share | 1.30 |
| Dividend Yield | 3.99% |
| Dividend Growth (YoY) | -20.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 65.86% |
| Buyback Yield | -0.06% |
| Shareholder Yield | 3.90% |
| Earnings Yield | 5.56% |
| FCF Yield | 3.72% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 16, 2013. It was a reverse split with a ratio of 0.719181284.
| Last Split Date | Dec 16, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.719181284 |
Scores
Taiyen Biotech has an Altman Z-Score of 3.75.
| Altman Z-Score | 3.75 |
| Piotroski F-Score | n/a |